Mechanisms and Therapeutic Implications of Microbiome‐Mediated Immune Dysregulation in Recurrent Pregnancy Loss and Implantation Failure
American Journal of Reproductive Immunology · 2026-03 · 95 (3)
DOI: 10.1111/aji.70219 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Reproductive Immunology, online erschienen am 14.03.2026. Verfasst von Wael Bahia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical and Molecular Biology, Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia. Hauptthemen laut MEDLINE: Abortion, Habitual, Dysbiosis, Gastrointestinal Microbiome, Microbiota. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Problem Recurrent pregnancy loss (RPL), defined as two or more consecutive pregnancy losses before 20 weeks of gestation, affects 1%–5% of couples of reproductive age worldwide. Growing evidence indicates a role for the microbiome in reproductive health, particularly in unexplained RPL. Method of Study Based on a review of literature from PubMed, EMBASE, and Web of Science databases from January 2020 to September 2025, this comprehensive overview explores the current understanding of the link between microbiome dysbiosis and RPL.
Results
Microbiome dysbiosis, especially a reduction in Lactobacillus dominance and increased diversity, is strongly linked to RPL across multiple reproductive sites. RPL is associated with the loss of protective Lactobacillus crispatus and a higher presence of potentially harmful bacteria, including Gardnerella vaginalis and Atopobium vaginae. An altered gut microbiome, particularly with lipopolysaccharide‐producing gram‐negative bacteria, contributes to systemic inflammation and immune dysfunction by disrupting maternal‐fetal immune tolerance. The microbiome‐immune axis is essential for establishing maternal‐fetal tolerance, with dysbiosis promoting pro‐inflammatory Th1/Th17 responses while suppressing regulatory T cells. Multiple mechanisms connect microbiome dysbiosis to RPL, including local inflammation, systemic immune issues, disruption of maternal‐fetal immune tolerance, molecular mimicry, and autoimmunity.
Conclusions
The microbiome is a promising new target for RPL treatment, with personalized microbial profiling and targeted therapies showing potential to improve pregnancy outcomes. Clinical implementation requires standardized protocols, larger randomized controlled trials, and validation of microbiome‐targeted interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Clinical and Molecular Biology, Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.
- Faculty of Sciences of Gafsa, Department of Biology, Campus Sidi Ahmed Zarouk, University of Gafsa, Gafsa, Tunisia.
- Faculté Des Sciences de Tunis, Université De Tunis El Manar, Tunis, Tunisia.
ORCID-Profile: Wael Bahia, Wassim Y Almawi
Zitieren
APA
Bahia, W., Soltani, I., Ferchichi, S., & Almawi, W. Y. (2026). Mechanisms and Therapeutic Implications of Microbiome‐Mediated Immune Dysregulation in Recurrent Pregnancy Loss and Implantation Failure. American Journal of Reproductive Immunology, 95(3). https://doi.org/10.1111/aji.70219
Vancouver
Bahia W, Soltani I, Ferchichi S, Almawi WY. Mechanisms and Therapeutic Implications of Microbiome‐Mediated Immune Dysregulation in Recurrent Pregnancy Loss and Implantation Failure. American Journal of Reproductive Immunology. 2026;95(3). doi:10.1111/aji.70219
BibTeX
@article{Bahia2026,
author = {Bahia, Wael and Soltani, Ismail and Ferchichi, Salima and Almawi, Wassim Y},
title = {Mechanisms and Therapeutic Implications of Microbiome‐Mediated Immune Dysregulation in Recurrent Pregnancy Loss and Implantation Failure},
journal = {American Journal of Reproductive Immunology},
year = {2026},
volume = {95},
number = {3},
doi = {10.1111/aji.70219}
}
EUVIMED